Insmed Incorporated (NASDAQ:INSM – Get Free Report) has been assigned a consensus recommendation of “Buy” from the sixteen research firms that are covering the company, MarketBeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $81.40.
INSM has been the topic of a number of recent research reports. Bank of America reiterated a “buy” rating and set a $83.00 price objective on shares of Insmed in a research note on Friday, July 5th. Truist Financial reduced their price target on Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Thursday, August 29th. Finally, The Goldman Sachs Group upped their price objective on shares of Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th.
Get Our Latest Analysis on INSM
Insider Activity
Institutional Trading of Insmed
Several hedge funds have recently made changes to their positions in INSM. EntryPoint Capital LLC purchased a new stake in shares of Insmed during the 1st quarter valued at approximately $33,000. Fidelis Capital Partners LLC acquired a new stake in shares of Insmed during the first quarter valued at about $34,000. First Horizon Advisors Inc. raised its stake in shares of Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 287 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Insmed in the 1st quarter valued at approximately $59,000. Finally, CWM LLC lifted its stake in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 155 shares in the last quarter.
Insmed Stock Performance
Insmed stock opened at $72.48 on Friday. Insmed has a 1-year low of $21.92 and a 1-year high of $80.53. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The firm has a market capitalization of $10.77 billion, a P/E ratio of -13.86 and a beta of 1.11. The company’s 50-day moving average is $74.29 and its 200 day moving average is $53.43.
Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. Insmed’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.78) earnings per share. Research analysts forecast that Insmed will post -5.42 EPS for the current year.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Articles
- Five stocks we like better than Insmed
- How to Start Investing in Real Estate
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 9/23 – 9/27
- Stock Sentiment Analysis: How it Works
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.